Le Lézard
Classified in: Health
Subjects: CHI, PER

Lurie Children's Appoints Dr. Thomas Shanley as President and CEO


CHICAGO, Dec. 6, 2019 /PRNewswire/ -- Ann & Robert H. Lurie Children's Hospital of Chicago today announced its Board of Directors has elected Thomas Shanley, MD, as President and CEO, effective immediately. Dr. Shanley succeeds Patrick M. Magoon, who served in this role for 22 years and will support the transition as Emeritus CEO for one year.

Lurie Children's Logo

Dr. Shanley previously served as Chair of Pediatrics at Northwestern University Feinberg School of Medicine and President and Chief Research Officer of Stanley Manne Children's Research Institute at Lurie Children's. He recently led the relocation of the Manne Research Institute to the new state-of-the-art facility within blocks of the hospital, strengthening the connection between the hospital's earliest phase of laboratory research and its clinical work, promoting a closer partnership between Lurie Children's, Northwestern University and the Feinberg School of Medicine.

"Dr. Shanley is an experienced leader with a strong focus on attracting top physicians and scientists, advancing treatments for excellence in children's health and encouraging an innovative workplace culture," said Roxanne Martino, Chair of Lurie Children's Board of Directors. "Since arriving at Lurie Children's four years ago, he has demonstrated his commitment to excellence and collaboration."

"I am honored and excited to be leading this outstanding institution," said Dr. Shanley. "I am confident that together we will build on our solid foundation and unprecedented momentum to become the leading children's hospital in the country. Together, we will transform childhood health and well-being to create healthier futures for the children of Chicago and beyond."

About Thomas Shanley, MD
Dr. Shanley came to Lurie Children's from the University of Michigan Medical School where he served as Associate Dean for Clinical and Translational Research, Professor of Pediatrics and Communicable Diseases, and Director of the Michigan Institute for Clinical and Health Research.

As a clinician, Dr. Shanley specialized in the treatment of children with hypoxemic respiratory failure from lung disease and septic shock triggered by infection. The broad goals of his research spanned from basic science to translational and clinical work, to improve understanding of the molecular basis of inflammatory diseases that afflict these critically ill young patients.

After earning a medical degree from the University of Chicago Pritzker School of Medicine, Dr. Shanley completed an internship and residency in pediatrics at the Children's Hospital of Philadelphia and a fellowship in pediatric critical care medicine at the University of Michigan.

Dr. Shanley has authored over 100 peer-reviewed publications and has received multiple teaching awards. In 2013, he received the Distinguished Service Hazinski Award from the Society for Pediatric Research, a national organization for which he was Secretary and Treasurer from 2008 to 2014. He also served as a member of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Study Section from 2005-2009. 

About Lurie Children's
Lurie Children's is ranked as one of the nation's top children's hospitals by U.S. News & World Report. The hospital serves as the pediatric training ground for Northwestern University Feinberg School of Medicine. Last year, Lurie Children's served more than 212,000 children from 49 states and 51 countries.

Media Contact: Public Affairs, 312-227-4600

SOURCE Lurie Children's


These press releases may also interest you

at 03:45
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screeningtm, announced today that the Medical Retina Center and the Diabetic Retinopathy Telescreening...

at 03:01
Sirona Biochem Corp. (US-OTC: SRBCF)("Sirona" or the "Company") announces that it has granted an aggregate of 6,800,000 incentive stock options to management, independent directors and consultants of the Company. The options, to purchase common...

at 03:01
In 2020, businesses can expect a range of regulations to be enforced, including the delayed Strong Customer Authentication (SCA) requirement of the Second Payment Services Directive (PSD2). This requires financial service providers to provide two...

at 03:00
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has repurchased 213,886 of its own shares in the period from 13 January 2020 up to and including 17 January 2020 at an average price of ?109.84. This is in...

at 03:00
Genomenon® announced that over 175,000 recently documented genetic variants (DNA mutations) have been added to the Mastermind® Genomic Search Engine in the 4th quarter of 2019, for a cumulative total of more than 5.9 million genetic variants. This...

at 02:35
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with CCL, to provide PredictSURE IBDtm...



News published on 6 december 2019 at 09:00 and distributed by: